

ASX Announcement



Medibio Limited – 3 March 2021

Medibio To Present at World Forum for Sleep Medicine

Melbourne, Australia and Minneapolis, MN – 3 March 2021: Medibio Limited (MEB or the Company)(ASX: MEB)(OTCPINK: MDBIF), is pleased to announce that two of its abstracts have been accepted at “SLEEP 2021,” the 35th annual meeting of the U.S. Associated Professional Sleep Societies (APSS) and the American Academy of Sleep Medicine, to be held virtually on June 10-13, 2021.

SLEEP 2021 is the premier world forum for the presentation and discussion of the latest developments in clinical sleep medicine and attended by worldwide experts sleep professionals. The meeting provides evidence-based education to advance the science and clinical practice of sleep medicine, disseminates cutting-edge sleep and circadian research, and promotes the translation of basic science into clinical practice.

Medibio’s abstracts presented are entitled:

- **Better and Faster Automatic Sleep Staging with Artificial Intelligence; and**
- **Heart Rate and Heart Rate Variability During Sleep As Biomarkers for Depression.**

Claude Solitario, Managing Director of Medibio said:

“The Sleep 21 Committee invites research abstracts from attendees world-wide, covering a wide range of sleep research topics. Many abstracts are reviewed by the Meeting’s Scientific Committee and acceptance is not guaranteed, only the latest breakthrough scientific work is selected for presentation. The acceptance of Medibio’s abstracts further validates the excellent work of the Company’s clinical team.”

– ENDS –

This announcement is authorised for release to the market by the Board of Directors of Medibio Limited

About Medibio Limited

Medibio (ASX: MEB) (OTCPINK: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTC Pink Open Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.

Medibio Investor and Media Enquiries:

Arthur Chan

WE Communications

WE-AUMedibio@we-worldwide.com

T: +61 (0) 404 369 388

Level 4, 100 Albert Road, South Melbourne, Vic 3205
Email: info@medibio.com.au | www.medibio.com.au
ACN: 008 130 336